Veraxa Biotech AG - Post de-SPAC
VRXAW- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0002079109
In the last 90 days, Veraxa Biotech AG - Post de-SPAC insiders filed 2 open-market purchases and 0 sales; 27 institutions reported holding it in 13F filings for Q2 2026, worth $992.5K in total; no superinvestor holds it.
Other share classesVRXA
Holders of 5% or more of VRXAW
Holders whose latest Schedule 13D or 13G filing reports 5% or more of Veraxa Biotech AG - Post de-SPAC, largest stake first. The change is against the holder's previous filing.
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Deck David Lukas | 13D | 18.00%25.5M shares | New | Jun 16, 20261 filing | Jun 16, 2026 | SEC |
| Xlife Sciences AG | 13D | 16.30%23.0M shares | New | Jun 15, 20261 filing | Jun 15, 2026 | SEC |
| European Molecular Biology Laboratory | 13D | 16.20%22.9M shares | New | Jun 16, 20261 filing | Jun 16, 2026 | SEC |
| Schoeni Gilbert Edgar | 13D | 15.90%22.5M shares | New | Jun 15, 20261 filing | Jun 15, 2026 | SEC |
Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.
13D and 13G filings
4 Schedule 13D and 13G filings on Veraxa Biotech AG - Post de-SPAC, newest first, including old-format filings without a stake.
| Filed (ET) | Filer | Form | Stake | Change | Event date | Filing |
|---|---|---|---|---|---|---|
| Jun 16, 20263:54 PM ET | European Molecular Biology Laboratory | 13D | 16.20%22.9M shares | New | Jun 10, 2026 | SEC |
| Jun 16, 20263:39 PM ET | Deck David Lukas | 13D | 18.00%25.5M shares | New | Jun 10, 2026 | SEC |
| Jun 15, 20263:46 PM ET | Xlife Sciences AG | 13D | 16.30%23.0M shares | New | Jun 10, 2026 | SEC |
| Jun 15, 20263:23 PM ET | Schoeni Gilbert Edgar | 13D | 15.90%22.5M shares | New | Jun 10, 2026 | SEC |
Form 144: proposed insider sales
Notices from officers, directors and other affiliates planning to sell Veraxa Biotech AG - Post de-SPAC shares.
No Form 144 notices for Veraxa Biotech AG - Post de-SPAC are on file.